Abstract:
:Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-cell lung cancer. Lorlatinib is a novel third-generation ALK TKI that is able to penetrate the blood-brain barrier and has broad-spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second-generation ALK TKIs. The safety profile of lorlatinib is distinct from those of other ALK TKIs. Adverse events are typically mild to moderate in severity, seldom result in permanent discontinuations, and are generally manageable through lorlatinib dose modifications and/or standard medical therapy. This article provides guidance to advanced practice providers (e.g., nurses, nurse practitioners, physician assistants) and oncology pharmacists for the clinical management of key lorlatinib-emergent adverse reactions (i.e., hyperlipidemias, central nervous system effects, bodyweight increase, edema, and peripheral neuropathy). As lorlatinib is both a substrate and inducer of the CYP3A enzyme system and is contraindicated with strong CYP3A inducers, relevant drug-drug interactions are also highlighted.
journal_name
Adv Therjournal_title
Advances in therapyauthors
Reed M,Rosales AS,Chioda MD,Parker L,Devgan G,Kettle Jdoi
10.1007/s12325-020-01365-3subject
Has Abstractpub_date
2020-06-01 00:00:00pages
3019-3030issue
6eissn
0741-238Xissn
1865-8652pii
10.1007/s12325-020-01365-3journal_volume
37pub_type
杂志文章abstract:INTRODUCTION:The healthcare sector contributes 5-8% of the global greenhouse gas emissions. Global and regional organizations and governments have started to design and implement measures to reduce global greenhouse gas emissions in the healthcare sector, e.g. by green public procurement policies and inclusion of ecolo...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01114-1
更新日期:2019-12-01 00:00:00
abstract::Recently, high levels of neurotrophic factors have been found in bronchial asthma; these factors include nerve growth factor, brain-derived neurotrophic factor, and leukemia inhibitory factor, among others. Neurotrophic factors are first synthesized in bronchial epithelial cells, immune cells, and other cells in the a...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/BF02848784
更新日期:2007-05-01 00:00:00
abstract:INTRODUCTION:Tumor necrosis factor (TNF-alpha) inhibitors, such as adalimumab, have shown success in treating autoimmune inflammatory diseases but are associated with substantial financial burdens to the healthcare system. Biosimilars, which are highly similar to biologic agents, offer the potential to reduce the finan...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-018-0851-5
更新日期:2019-02-01 00:00:00
abstract::Human papillomavirus (HPV) infection is one of the most common sexually transmitted infections in adolescents. Such infection is associated with substantial health risks and is unpredictable in its resolution. Genital warts are the most common clinical manifestations of genital HPV infections. Most genital warts are c...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/BF02849928
更新日期:2005-05-01 00:00:00
abstract::This double-blind, randomized, prospective study was conducted to compare the analgesic and sedative efficacy of fentanyl and meperidine in orthopedic closed reduction of fractures and dislocations undertaken in the emergency department. Seventy consecutive adult patients with fractures or dislocations suitable for re...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1007/BF02850035
更新日期:2004-09-01 00:00:00
abstract::Pregnancy in adolescence has been and continues to be a problem in public health. The purpose of this study was to investigate obstetric outcomes of adolescent pregnancies in Samsun, Turkey. A cross-sectional study was conducted between January 1 and December 31, 2004, at 3 hospitals in Samsun, Turkey. Of the 10,100 w...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02849957
更新日期:2005-11-01 00:00:00
abstract:PURPOSE:A recent successful clinical trial demonstrated that a less invasive cell-injection procedure is a viable medical modality for treating corneal endothelial dystrophy. This medical advance still relies on human corneal endothelial cell (HCEC) sources derived from rare cornea donations. The progenitor of the corn...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-020-01237-w
更新日期:2020-03-01 00:00:00
abstract:INTRODUCTION:Anti-vascular endothelial growth factor therapy is the standard of care for neovascular age-related macular degeneration (nAMD). The dosage of two licensed agents, ranibizumab and aflibercept, was established through clinical trials; however, it is unclear if either agent is administered as recommended in ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-017-0624-6
更新日期:2017-12-01 00:00:00
abstract::Alpha-mannosidosis is a rare lysosomal storage disorder that generally presents in early childhood. It is a progressive, highly heterogeneous disease that is difficult to recognize, and a diagnosis is usually reached after referrals to multiple specialists. It is important to understand the challenges faced by patient...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01574-w
更新日期:2020-11-24 00:00:00
abstract:INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is limited. METHODS:We u...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01380-4
更新日期:2020-07-01 00:00:00
abstract:INTRODUCTION:The anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) alectinib was approved in Japan in 2014 for the treatment of ALK fusion gene-positive advanced non-small cell lung cancer (NSCLC). With the approvals of crizotinib in 2012 and ceritinib in 2017, Japan became the first country with multipl...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01392-0
更新日期:2020-07-01 00:00:00
abstract::Coronary heart disease is the major cause of morbidity and mortality in industrialized countries, and its prevalence is predicted to grow as the population ages. Current drugs for chronic stable angina (such as beta-blockers, calcium-channel blockers, long- and short-acting nitrates, and potassium-channel activators) ...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-009-0005-x
更新日期:2009-02-01 00:00:00
abstract::In order for the global healthcare system to remain sustainable, healthcare spending needs to be reduced, and self-treating certain conditions under the guidance of a pharmacist provides a means of accomplishing this goal. This article was developed to describe global healthcare trends affecting self-care with a speci...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-016-0395-5
更新日期:2016-10-01 00:00:00
abstract:INTRODUCTION:Aripiprazole and olanzapine are atypical antipsychotics. Both drugs can induce metabolic changes; however, the metabolic side effects produced by aripiprazole are more benign. The aim of the study was to evaluate if aripiprazole and olanzapine alter prolactin levels, lipid and glucose metabolism and hepati...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01566-w
更新日期:2020-12-05 00:00:00
abstract::Intensive postremission chemotherapy has produced disease-free survival comparable to that of bone marrow transplantation in patients with acute myelogenous leukemia (AML), but its efficacy was unknown in Taiwan. We assessed the efficacy of intensive postremission chemotherapy, consisting of high-dose arabinoside-C (H...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02852390
更新日期:2001-03-01 00:00:00
abstract:INTRODUCTION:Clinical guidelines recommend levothyroxine as the standard of care for hypothyroidism and that patients should be treated with a consistent preparation of synthetic levothyroxine without switching among formulations. This study examines the likelihoods of negative clinical outcomes between continuous user...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01537-1
更新日期:2020-10-28 00:00:00
abstract::The article "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA", written by Pierre Johansen, Barnaby Hunt, Neeraj N. Iyer, Tam Dang-Tan, Richard F. Pollock was originally published...
journal_title:Advances in therapy
pub_type: 已发布勘误
doi:10.1007/s12325-019-00945-2
更新日期:2019-05-01 00:00:00
abstract::Patients with severe gastrointestinal motility disorders are often found to have intravenous access clots or deep venous thrombosis. It has previously been reported that many patients who have intravenous access thrombosis have concomitant thrombotic risk factors. In this study, the goal was to determine the underlyin...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02850315
更新日期:2006-09-01 00:00:00
abstract:INTRODUCTION:To assess the impact of certolizumab pegol (CZP) treatment on clinical, patient-reported, and musculoskeletal ultrasound outcomes and to determine the treatment response time point most predictive of long-term outcomes in Italian patients with rheumatoid arthritis (RA). METHODS:CZP-SPEED (NCT01443364) was...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1007/s12325-018-0751-8
更新日期:2018-08-01 00:00:00
abstract::Adenoid cystic carcinoma (AdCC) of the head and neck is a well-recognized pathologic entity that rarely occurs in the larynx. Although the 5-year locoregional control rates are high, distant metastasis has a tendency to appear more than 5 years post treatment. Because AdCC of the larynx is uncommon, it is difficult to...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-016-0311-z
更新日期:2016-04-01 00:00:00
abstract::The article "Sleep Quality and Congestion with Breathe Right Nasal Strips: Two Randomized Controlled Trials", written by Michael J. Noss, Renee Ciesla, and Gilbert Shanga, was originally published electronically on the publisher's internet portal (currently SpringerLink) on June 17, 2019 without Open Access. The artic...
journal_title:Advances in therapy
pub_type: 已发布勘误
doi:10.1007/s12325-019-01069-3
更新日期:2019-11-01 00:00:00
abstract:INTRODUCTION:Comparisons between brand and biosimilar basal insulin in hospitalized patients are lacking. We aimed to compare the efficacy and safety of brand insulin glargine vs. biosimilar insulin glargine in non-critical hospitalized patients with type 2 diabetes mellitus (T2DM). METHODS:This retrospective study wa...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-00922-9
更新日期:2019-05-01 00:00:00
abstract:PURPOSE:To evaluate the impact on cost, time, resource use, and clinic workflow of converting the route of drug administration from a neurokinin-1 receptor antagonist (NK-1 RA) 30-min intravenous (IV) infusion to aprepitant IV, and more specifically to IV push, within a multicenter community oncology practice. METHODS...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01377-z
更新日期:2020-07-01 00:00:00
abstract:INTRODUCTION:Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)-collectively named inflammatory arthritis (IA). However, the costs associated with swit...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01425-8
更新日期:2020-09-01 00:00:00
abstract::The lipid-lowering effect of a carob pulp preparation rich in insoluble dietary fiber and polyphenols was investigated in a noncomparative, open-label pilot study. Over 8 weeks, 47 volunteers with moderate hypercholesterolemia (total cholesterol 232-302 mg/dL) consumed 15 g of carob per day in three products (breakfas...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02853169
更新日期:2001-09-01 00:00:00
abstract:INTRODUCTION:Benefit and risk of anticoagulation in cirrhotic patients with portal vein thrombosis (PVT) remain controversial, especially in those with asymptomatic PVT and in non-liver transplant candidates. Furthermore, the predictors of portal vein recanalization and bleeding events after anticoagulation are critica...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01550-4
更新日期:2020-11-05 00:00:00
abstract::Despite the results from clinical trials in patients with hypertension and the development of a long list of guidelines for the management of hypertension, many physicians and other healthcare professionals still manage hypertension using approaches that clearly diverge at least partially from the recommendations of t...
journal_title:Advances in therapy
pub_type: 共识发展会议,杂志文章,评审
doi:10.1007/BF02849881
更新日期:2005-03-01 00:00:00
abstract:INTRODUCTION:Liraglutide has been widely used in the treatment of type 2 diabetes mellitus (T2DM), however, the results of a number of randomized placebo-controlled trials on the effects of liraglutide for the treatment of T2DM have varied. The purpose of this study was to assess the effects of liraglutide versus place...
journal_title:Advances in therapy
pub_type: 杂志文章,meta分析
doi:10.1007/s12325-014-0164-2
更新日期:2014-11-01 00:00:00
abstract:OBJECTIVES:Because clinical guidelines do not offer clear recommendations for treatment options after discontinuing a tumor necrosis factor (TNF) blocker, this study evaluated treatment patterns within 360 days after discontinuation of TNF-blocker treatment. METHODS:The IMS LifeLink Health Plan Claims database was use...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-014-0110-3
更新日期:2014-04-01 00:00:00
abstract:INTRODUCTION:Acute gastrointestinal bleeding (GIB) is a major cause of death in liver cirrhosis. This multicenter study aims to develop and validate a novel and easy-to-access model for predicting the prognosis of patients with cirrhosis and acute GIB. METHODS:Patients with cirrhosis and acute GIB were enrolled and ra...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/s12325-019-01083-5
更新日期:2019-11-01 00:00:00